Company news
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) news
Rhythm Pharmaceuticals, Inc. news releases on 6ix. Latest, Apr 6, 2025: Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND…
Press releases — page 2
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
April 5, 2025
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
March 19, 2025
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
March 18, 2025
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration
March 17, 2025
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
February 25, 2025
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025
February 12, 2025
Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February
February 4, 2025
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones
January 9, 2025
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old
December 19, 2024
Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to in...
December 2, 2024
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide
November 17, 2024
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology
November 12, 2024
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
November 12, 2024
Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update
November 4, 2024
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024
November 3, 2024
Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome
October 23, 2024
Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024
October 22, 2024
Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September
August 25, 2024
Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old
August 25, 2024
Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update
August 5, 2024
Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old
July 30, 2024
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
July 22, 2024
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity
July 22, 2024
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
July 7, 2024
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
June 27, 2024
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
June 2, 2024
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
June 2, 2024
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
May 21, 2024
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
May 6, 2024
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
May 5, 2024
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
April 28, 2024
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
April 23, 2024
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
March 31, 2024
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
March 24, 2024
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
March 5, 2024
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
February 21, 2024
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
February 21, 2024
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
February 6, 2024
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
January 30, 2024
Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
January 3, 2024
Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
January 3, 2024
Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023
December 12, 2023
Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event
December 5, 2023
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
November 6, 2023
Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)
November 1, 2023
Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
October 24, 2023
Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023
October 16, 2023
Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®
October 9, 2023
Rhythm Pharmaceuticals Presents New Data at ESPE 2023
September 21, 2023
Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
September 18, 2023